Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 0.00 0.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8576 to 8600 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
14/4/2020
11:36
SV, Indeed. But at least the R and D side (which is where we will get the potential big pay day from) is relatively unaffected and the company is pressing on as quickly as possible with this.
langland
14/4/2020
11:13
Just as I thought things had settled.
semper vigilans
09/4/2020
09:33
That is correct. It also goes to show why AOR has decided to reinvent itself as a medical device co,in order to capture the value chain that is not realised through licensing Elasteon to third parties. The one thing that is becoming very clear however is the quality of Elasteon and how it has been under-sold in the past.
greedy rooster
08/4/2020
12:19
Bones- completely agree. Working out revenue from this is not that much of relevance. But the wider market for Elasteon and blood contact properties it represents for medical devices is far more important for wider adoption. Aortech wanted to promote this and the Rua recent deal will certainly do this with their existing/new clients.
nimbo10
08/4/2020
10:58
Nimbo10, I am in the dark on this kind of confidential commercial data but we were advised on 30th March that: “....two of the Elast-Eon(TM) enabled devices that represent a large proportion of annual Elast-Eon(TM) demand are ECMO (extracorporeal membrane oxygenation) cannulae which are used to oxygenate a patient's blood when ventilation is not sufficient to assist in lung failure. AorTech is proud to be associated with these products which are helping the most critically ill Coronavirus patients....” My understanding is that Aortech receives licence fees and royalties on the use of Elast-Eon within medical devices when those devices are manufactured and/or sold by the licensee. Quite what proportion of the selling prices relates to Elast-Eon and what percentage relates to royalties or fees, I do not know. I assume relatively small but if a large demand appears for these cannulae, that must work in Aortech’s favour. You mention the cost of supporting a patient with ECMO cannulae but I would not think the hospital costs will figure in calculating the royalties. It could suggest though that the price of the devices is quite high and that would be relevant. What may be of greater value here is the reputation and wider knowledge of the benefits of Elast-Eon in vital medical devices.
bones
08/4/2020
10:28
If a ventilator helps the lungs, Ecmo dispenses with them entirely. It takes the patient’s blood supply and oxygenates it directly, giving the most severe cases breathing space, so to speak, to recover. The average cost of Ecmo treatment for one patient is £45,000 How much would Aortech be making from the Canula?
nimbo10
04/4/2020
10:38
I am of the view that the RUA merger is important for relationships with majors in the US. Bill Brown and David Richmond went to California in February presumably with an idea that they would be merging already in play and I suggest had conversations with people to (1) ensure that RUA’s existing business with the main customers would be secure under the merger, and (2) promote a much more rounded outfit that is vertically integrated and can offer a wide range of services and products involving Elasteon and all that goes with it. I think that makes AOR/RUA a potential target down the line for a bigger but maybe midsized MedTech company to snaffle up in the right circumstances. The deferment by David R was, I believe, a very good move as that buys a lot of time for AorTech/RUA on the financing and R&D side. This would fend off any opportunistic lowball approaches given the huge potential still on offer here. I still think we are in the foothills of the proverbial mountain.
bones
03/4/2020
20:47
Good spot nimbo10. The 50k looks definitive at 95p. The after hours one of 25k at 90 is harder to define as it seems to be a worked order not declared til late. Either way, it looks like there is good support here. Today’s action was mostly small bed and isa switches by the look of the pairs that went through. It was the last trading day of the tax year so it was unsurprising to see some of these pass through.
bones
03/4/2020
18:32
Looks like there was a 50k and 25k buys yest reported today? Maybe that was one of drivers for move yest, anyway give good confidence.
nimbo10
02/4/2020
14:35
RNS out reflecting the adjustment for increased number of shares in issue.
langland
02/4/2020
11:48
Nice to see some further recovery today. Perhaps more people have got round to reading the Equity Development update released the other day.
langland
01/4/2020
19:00
Significant ( > 3% )shareholders now updated in header to include David Richmond, CEO. All the others in the list are shown with the same quantities of shares as reported in October 2019 but I suspect some of these are out of date by now given some of the violent moves and general selling there has been by retail investors since then. Maybe a few of the nominee groups like Walker Crips, AJ Bell, Hargreaves, etc will update their current interests following this adjustment, but a lot just don't seem to bother themselves with holdings RNS's on AIM :)
bones
01/4/2020
18:37
From "Scottish Business Insider" magazine: Https://www.insider.co.uk/news/aortech-resumes-production-part-covid-21784385 "Irvine-based RUA Medical Devices and Dundee firm AorTech help make devices which could save patients Ayrshire-based life sciences business RUA Medical Devices has resumed operations after two of its customers were deemed vital to saving coronavirus patients. The Irvine firm had suspended production temporarily last week but reopened on Monday, with social distancing measures in place, after being designated as part of the critical supply chain for the healthcare sector. Meanwhile, Dundee-based Aortech - which is in the process of buying RUA - has revealed that it is also playing a critical role in the Covid-19 supply chain. Its Elast-Eon polymer is used to make cannulas which are used to pump oxygenated blood into a patient’s body if their lungs stop working, even with a ventilator. AorTech has struck a deal to delay half of its payment to David Richmond for the acquisition of RUA Medical Devices. Richmond, who is already a non-executive director of AorTech and will become chief executive of the enlarged group following the £2.45 million takeover, has agreed to defer £425,000 of the £950,000 cash he will receive for up to two years. He will only receive a payment due in April 2021 if RUA generates a certain amount of cash in the year to 31 March 2021. The company is to be renamed RUA. AorTech said the deal with Richmond would allow it to fund its research and development work in the year ahead. It added that conserving cash would also help it to weather any short-term disruption to trading caused by Covid-19. The company said: “AorTech is proud to be associated with these products which are helping the most critically ill coronavirus patients.” The firm added: “It is too early to quantify fully the impact of Covid-19 on the group’s business. The board is confident that the enlarged group is well equipped and operating in an essential industry to enable both AorTech and RUA to withstand this near-term uncertainty.”"
bones
01/4/2020
15:46
An impressive £15k worth bought by someone at 71p at lunchtime.
bones
01/4/2020
14:46
Well said, langland. I met David Richmond at the AGM last August and I was personally very impressed with his commercial drive, the way he spoke about the business and hearing his back story (With five generations of his family having worked in the fabrics sector I think I heard him say). He has himself run a number of successful enterprises coming through the fabric manufacturing sector, leading eventually to the specialist fabric-based medical devices that RUA is now expert in. Add to that RUA’s fast-improving knowledge of how to incorporate Elast-Eon into these devices, David Richmond and Bill Brown must now be inspired to drive this trailblazing company forward and educate the majors about the future!
bones
01/4/2020
14:10
Announcement of Mr. Richmond's new holding. I don't think anyone could argue that the BOD's and shareholders' interests are not aligned.
langland
31/3/2020
12:48
Link below gives a bit of background on ECMO treatment for COVID-19, Elast-Eon is used in these devices hTTps://uk.news.yahoo.com/coronavirus-nhs-doctor-warns-already-breaking-point-174100415.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuYmluZy5jb20vc2VhcmNoP3E9ZWNtbytpbit1cytmb3IrY29yb25hdmlydXMrcGF0aWVudHMmRk9STT1RU1JFMg&guce_referrer_sig=AQAAACpceBsiVGvfPgNe6trKlf2zM-goUchRE3xpqQEUIqBZ6S7WZQrJq9VC7egasOb_51mbmmCTNWQpbe17UKzBV9WdON6NipIbMZy4tOHgijNte-jxdvBDV2fmAiZ8asUdHAAa8tF67EoNr4fuKx1eNZ_zR8LJ28UsJ7sPgHAXwHOL
landy90
31/3/2020
12:43
latest update post RUA acqustion is here: https://equitydevelopment.co.uk/edreader/?d=%3D%3DgNwcjM
edmonda
31/3/2020
12:36
I think we all do Bones!
semper vigilans
31/3/2020
12:14
SV, yes but he’s already taken 60% of the deal in shares, paying £1 to boot for each one! That gives him near enough 10% of the company and the risk that goes with that. He is well aligned now as a major shareholder and the CEO to grow this company strongly. I wish him every success!
bones
31/3/2020
10:59
Better to lend the company £425k then buy a few in the market, than for him to have converted the loan into more shares.
semper vigilans
31/3/2020
10:40
You drive a hard bargain, GR! Poor soul has just lent the company £425k :)
bones
31/3/2020
10:36
Wouldn't be surprised if Dave Richmond puts his hand in his pocket and buys shares shortly after completion. Would send a good message to the overlookers.
greedy rooster
31/3/2020
10:26
Good points well made.
langland
31/3/2020
10:20
I think it worth mentioning, lest we all forget, that the overarching theme of introducing Elast-Eon into the medical device world is its proven use and effectiveness in existing blood-contacting devices due to its unique biocompatibility, etc, not matched by any other non-tissue materials. Hence, Aortech/RUA is developing cardiovascular grafts, patches and heart valves for eventual trial. What Aortech/RUA is doing is really important, in today’s environmentally focussed world, not least pioneering materials that can supersede the current practice of sourcing materials derived from animals. Currently, a giant industry relies on animal sourced product but it is accepted that this has supply issues as well as becoming less acceptable to society that is concerned with the industrialisation of animals in general. If it is good enough to promote vegetarian and vegan habits in food production worldwide, then it should follow that the same principles should apply to medical advances when there are “alternatives to meat”. Which makes me wonder how this whole Covid-19 pandemic will make the industry consider whether to redouble its efforts to wean itself away from using animal-derived products. We know that the sealants used from animals are ultra-safe from a medical and regulatory standpoint but the overall acceptance by the public in the longer run of transferring animal derivative into the human body must have an effect on perceptions of what is acceptable, I would argue. We know that Aortech/RUA is in constant dialogue with the medical device industry over its Elast-Eon development projects and this is no real surprise. I don’t believe that any company has the rights to the leading technology that Aortech/RUA possesses and ultimately, the industry may get itself into gear for change!
bones
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200706 03:53:14